Sarepta Therapeutics (Brazil) Top Management
S1RP34 Stock | BRL 21.64 0.56 2.66% |
Sarepta Therapeutics employs about 840 people. The company is managed by 10 executives with a total tenure of roughly 1960 years, averaging almost 196.0 years of service per executive, having 84.0 employees per reported executive. Analysis of Sarepta Therapeutics' management performance can provide insight into the company performance.
William Ciambrone Insider Ex Operations |
Dallan Murray Insider VP Officer |
Sarepta |
Sarepta Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1149) % which means that it has lost $0.1149 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.591) %, meaning that it generated substantial loss on money invested by shareholders. Sarepta Therapeutics' management efficiency ratios could be used to measure how well Sarepta Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Sarepta Therapeutics Workforce Comparison
Sarepta Therapeutics is currently regarded as top stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 156,687. Sarepta Therapeutics maintains roughly 840 in number of employees contributing less than 1% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.82) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.61) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.61. Sarepta Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Sarepta Therapeutics Price Series Summation is a cross summation of Sarepta Therapeutics price series and its benchmark/peer.
Sarepta Therapeutics Notable Stakeholders
A Sarepta Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sarepta Therapeutics often face trade-offs trying to please all of them. Sarepta Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sarepta Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
William Ciambrone | Ex Operations | Profile | |
Dallan Murray | VP Officer | Profile | |
Ian Estepan | Ex CFO | Profile | |
Douglas Esq | CEO Pres | Profile | |
Alison Nasisi | Chief VP | Profile | |
Bilal Arif | VP Operations | Profile | |
Diane Berry | Sr Affairs | Profile | |
Ryan Brown | Gen VP | Profile | |
Louise RodinoKlapac | Chief VP | Profile | |
Mary Jenkins | Sr Relations | Profile |
About Sarepta Therapeutics Management Performance
The success or failure of an entity such as Sarepta Therapeutics often depends on how effective the management is. Sarepta Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sarepta management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sarepta management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. SAREPTA THERDRN operates under Biotechnology classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 866 people.
Please note, the presentation of Sarepta Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sarepta Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sarepta Therapeutics' management manipulating its earnings.
Sarepta Therapeutics Workforce Analysis
Traditionally, organizations such as Sarepta Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sarepta Therapeutics within its industry.Sarepta Therapeutics Manpower Efficiency
Return on Sarepta Therapeutics Manpower
Revenue Per Employee | 835.6K | |
Revenue Per Executive | 70.2M | |
Net Loss Per Employee | 498.5K | |
Net Loss Per Executive | 41.9M |
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |